Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

accelerated the rate of viral clearance, with comparable response at ANA598 doses of 200 mg bid and 400 mg bid.  ANA598 also showed an excellent safety profile in the study through the 12 weeks of dosing, with reported adverse events being typical for patients treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Slides from the oral presentation are available on the Company's website at www.anadyspharma.com.On November 2, 2010, additional data from the ongoing Phase IIa trial were presented at AASLD showing that the addition of ANA598 to SOC conferred benefit in both the patients with the IL-28B genotypes most and less responsive to SOC in a poster titled, "IL28B Polymorphism and Kinetics of Antiviral Activity for ANA598 in Combination with Pegylated Interferon alpha 2A Plus Ribavirin in Treatment-Naïve Genotype-1 Chronic HCV Patients."  The poster is available on the Company's website at www.anadyspharma.com.


  • Phase IIa Study of ANA773 in HCV.  In October, Anadys announced that it plans to resume clinical investigation of ANA773 in hepatitis C patients.  ANA773 is an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway.  The Company intends to conduct a 28-day study of ANA773, in combination with ribavirin in the first cohorts and as triple therapy in combination with ribavirin and a direct-acting antiviral (DAA) in subsequent cohorts. Anadys intends to conduct this study in Europe and potentially other countries, and expects that up to approximately 75 patients will participate in the trial, inclusive of the DAA cohorts.Recent Operational Highlights

  • Closed Underwritten Public Offering of Common Stock.  In October, Anadys closed an underwritten public offering through the sale of c
    '/>"/>


  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/20/2014)... 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, in ... its Mylan-Nitro Spray 0.4 mg/metered dose due to the product ... component. A missing "dip tube" could pose ... patient. This defect may lead patients to believe they are ... access it. Not receiving nitroglycerin could place them at risk ...
    (Date:9/19/2014)... Pa. , Sept. 19, 2014  Today ... two new variable angle plating systems featuring its ... surgeons can adapt screw trajectory to match patient ... specific fragments of bone. The systems are being ... & Ankle Society (AOFAS) and the International Federation ...
    (Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
    Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
    ... , SAN DIEGO, Oct. 15 Prometheus Laboratories ... announced the nationwide commercial launch of three new ... Dx and ProOnc Mesothelioma Dx. Each of these ... microRNA technology. , "Prometheus has a long and ...
    ... HOLLYWOOD, Fla. and PRINCETON, N.J., Oct. 15 ... preclinical and pharmaceutical product development services and PharmaNet ... development services to innovative pharmaceutical, biotechnology, generic drug ... the completion of a business development and co-promotion ...
    Cached Medicine Technology:Prometheus Launches ProOnc Dx Cancer Diagnostics 2Prometheus Launches ProOnc Dx Cancer Diagnostics 3Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance 2
    (Date:9/21/2014)... of preterm birth the birth of an infant ... significant health problem that has increased over the past ... Control and Prevention (CDC), preterm birth affects nearly 500,000 ... in the U.S. While medical care has improved survival ... positively impact the neurodevelopmental outcomes of preterm infants. , ...
    (Date:9/21/2014)... of the leading online stores of real and synthetic hair ... human hair lace wigs inspired by 6 famous celebrities. It’s ... latest celebrity hairstyles are. , For people who ... to choose from: a style of yaki straight lace wig, ... ombre red lace wig. People can go to the product ...
    (Date:9/21/2014)... public health authorities focus on the physical activity benefits ... of Montreal reveals that for children, playing has no ... activity that is fun, done alone or with friends, ... pleasure, but also to combat boredom, sadness, fear, or ... play, authorities put aside several aspects of play that ...
    (Date:9/21/2014)... Dry roasted peanuts are more likely to trigger an ... University study involving mice. , The researchers say that ... the dry roasting process are recognised by the body,s ... allergic immune response the next time it sees any ... the number of people with peanut allergies in the ...
    (Date:9/21/2014)... The Laboratory Testing Services industry is composed ... on items ranging from consumer and food products to ... operators to ensure the safety and quality of their ... government safety regulations and consumer lawsuits have led to ... revenue briefly dipped in 2009 as the US economy ...
    Breaking Medicine News(10 mins):Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
    ... 3 Nanophase Technologies (Nasdaq: ... and advanced nanoengineered products, announced today that the Company ... 28th, as its Chief Technology Officer, so that he ... was responsible for several of the Company,s key patents ...
    ... National Center for Health Care Informatics (NCHCI) Presented Pilot ... a Patriot Scientific company (OTC Bulletin Board: PTSC), announced ... and the National Center for Health Care Informatics (NCHCI), ... a presentation today by Raymond F. Rogers, chief executive ...
    ... brand made specifically for kids by kids and their ... WAT-AAH!, the first sugar-free, functional water brand made specifically ... first official "WAT-AAH! Challenge" to defy the expectation that ... the month of March, mothers who participate in the ...
    ... released today by Dr. Jane L. Delgado, President and ... nation,s leading Hispanic health advocacy group."We congratulate Governor Sebelius ... Health and Human Services and Nancy-Ann DeParle on her ... Health Reform."The nation will be well served at this ...
    ... Inc. (Nasdaq: GTIV ), a leading provider ... plans to present at two upcoming investor conferences. Gentiva ... in Miami, Florida from 9:30 a.m. to 9:55 a.m. ... Annual Raymond James Institutional Investor Conference in Orlando, Florida ...
    ... meal of the day has surprising impact on young ... awareness for the importance of breakfast for students, Sodexo, ... more than 470 school districts across the country, has ... Students" in time for National School Breakfast Week, March ...
    Cached Medicine News:Health News:Nanophase Announces Changes in Principal Officers and Directors 2Health News:Nanophase Announces Changes in Principal Officers and Directors 3Health News:Crossflo Health Information Exchange Project Presented at HP Health and Life Sciences Symposium 2Health News:Crossflo Health Information Exchange Project Presented at HP Health and Life Sciences Symposium 3Health News:Let Water Be Water, LLC Introduces New 'WAT-AAH! Challenge' 2Health News:National Alliance for Hispanic Health Congratulates Governor Kathleen Sebelius and Nancy-Ann DeParle 2Health News:Gentiva(R) Health Services to Present at Upcoming Investor Conferences 2Health News:Gentiva(R) Health Services to Present at Upcoming Investor Conferences 3Health News:Sodexo Shares Top Breakfast Benefits for Students 2
    ... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
    ... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
    Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
    Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
    Medicine Products: